List of Refereed Journals published by UGC, New Delhi on 28-03-2017-- AJRC (Sr. No.-1025); AJM (Sr. No.-2497); RJET (Sr. No.-7220); RJPP (Sr. No.- 7232): RJPPD (Sr. No.- 7234); RJPT (Sr. No.-7235) (19-Apr-2017)        | List of Refereed Journals published by UGC, New Delhi on 11-01-2017-- Research Journal of Pharmacy and Technology (Sr. No.-275); Asian Journal of Management (Sr. No.-3986); Asian Journal of Research in Chemistry (Sr. No.-4008); Research Journal of Engineering and Technology (Sr. No.-31787); Research (22-Jan-2017)        |

Journal :   Research Journal of Pharmacy and Technology

Volume No. :   2

Issue No. :  4

Year :  2009

Pages :   

ISSN Print :  0974-3618

ISSN Online :  0974-360X


Registration

Allready Registrered
Click to Login

Future of Cancer Therapy-COX-2 Inhibitors: A Review



Address:   1Department of Pharmacology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal-506002, Andhra Pradesh. 2Department of Pharmaceutics, J.K.K.M.M.R.F. College of Pharmacy, Komarapalayam, Pin
638183, Namakkal, Tamilnadu 3Departme
DOI No: Not Available

ABSTRACT:
Cycloxygenases (COX) are the principle enzymes involved in the metabolism of arachidonic acid generating prostaglandins which are the genuine mediators of inflammation and pain. COX are classified into Type-1 and Type-2 which are constitutive and inducible respectively. Recent research has brought into light the possible role of these PGs in the COX-2 cascade of tumor proliferation, angiogenesis and metastasis with significant overexpression. Thus COX-2 can serve as a useful biomarker in the early diagnosis and can be selectively targeted in the tumour cells with greater proven safety. The review deals with the potential role of COX-2 inhibitors in canceling the PG mediated Signaling, the role of COX-2 in different types of cancers. (Lung, Head and Neck, Bladder, Cervical Cancer and Other Oncology applications), the beneficial outcomes of combination therapy of COX-2 inhibitors along with either chemotherapy or radiotherapy. In conclusion a note on future research options for treating neuroblastomas with COX-2 inhibitors was elucidated.
KEYWORDS:
Cycloxygenases, Prostaglandins, cancer, angiogenesis and over expression.
Cite:
Not Available
[View HTML]     



Visitor's No. :   174630